| Hans-Günter Meyer-Thompson | Legal
USA. Indivior's shares rise after US court blocks Dr Reddy's generic drug
USA. Indivior's shares rise after US court blocks Dr Reddy's generic drug
Indivior stuck to its 2018 revenue guidance on Friday but said it would revisit the forecast if Dr Reddy's launches the cheaper drug. (business-standard.com, UK, 18.06.2018)